The US Preventive Services Task Force recommends use of preexposure prophylaxis (PrEP) for individuals at risk of acquiring HIV 1 The Centers for Disease Control and Prevention estimated that 1 1 million US individuals might benefit from PrEP,2 but only 7% of those used it in 2016 3 Clinicians have been slow to prescribe PrEP, citing concerns regarding its effectiveness outside a clinical trial setting, unintended consequences, and ambiguity surrounding which type of clinician is best suited to prescribe PrEP 4 Using a commercial insurance database, this study examined trends in the number of persons prescribed PrEP, prescriptions for PrEP, and specialty of prescribing clinicians
Trends in HIV preexposure prophylaxis prescribing in the United States, 2012-2018